NO782455L - PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE AMIDINO-BENZYLPYRIMIDINES - Google Patents

PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE AMIDINO-BENZYLPYRIMIDINES

Info

Publication number
NO782455L
NO782455L NO782455A NO782455A NO782455L NO 782455 L NO782455 L NO 782455L NO 782455 A NO782455 A NO 782455A NO 782455 A NO782455 A NO 782455A NO 782455 L NO782455 L NO 782455L
Authority
NO
Norway
Prior art keywords
pyrimidin
trimethoxybenzyl
amino
phenyl
methyl
Prior art date
Application number
NO782455A
Other languages
Norwegian (no)
Inventor
Peter Scharwaechter
Klaus Gutsche
Wilhelm Kohlmann
Elmshorn Gerhard
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of NO782455L publication Critical patent/NO782455L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Description

Denne oppfinnelse angår fremstilling av nye amidino-benzylpyrimidiner med den generelle formel I This invention relates to the preparation of new amidino-benzylpyrimidines of the general formula I

12 3 hvor R , R og R , som kan være like eller forskjellige fra hverandre, betyr hydrogen, metyl, metoksy eller klor, R 4betyr alkyl med 1-6 C-atomer eller benzyl, og R 5 og R 6, som kan være like eller forskjellige fra hverandre, betyr hydrogen, lavere alkyl med 1-4 C-atomer, eventuelt substituert benzyl eller fenyl, cykloheksyl, adamantyl eller furfuryl, eller en av resteneR^ 6 7 1 12 3 where R , R and R , which can be the same or different from each other, means hydrogen, methyl, methoxy or chlorine, R 4 means alkyl with 1-6 C atoms or benzyl, and R 5 and R 6 , which can be the same or different from each other, means hydrogen, lower alkyl with 1-4 C atoms, optionally substituted benzyl or phenyl, cyclohexyl, adamantyl or furfuryl, or one of the residues R^ 6 7 1

eller R betyr gruppen -CgH^-SC^-NH-R , hvor R betyr restenor R means the group -CgH^-SC^-NH-R , where R means the residue

eller en heterocyklisk ring med 1 til 3 heteroatomer som kan være like eller forskjellige fra hverandre og er nitrogen eller oksygen, og kan være substituert med klor, alkyl med 1 til 4 karbonatomer eller metoksy og består av 5-6 ringledd, eller R 5 og R^ danner sammen med nitrogenatomet som de er bundet til, en or a heterocyclic ring with 1 to 3 heteroatoms which may be the same or different from each other and is nitrogen or oxygen, and may be substituted by chlorine, alkyl with 1 to 4 carbon atoms or methoxy and consists of 5-6 ring members, or R 5 and R^ forms together with the nitrogen atom to which they are bound, a

mettet heterocyklisk ring med 5-7 ledd, som eventuelt kan inne-holde et oksygenatom eller gruppen >N-Y hvor .Y betyr metyl, saturated heterocyclic ring with 5-7 members, which may optionally contain an oxygen atom or the group >N-Y where .Y means methyl,

benzyl eller fenyl,benzyl or phenyl,

og farmakologisk forlikelige salter med vanlige syrer.and pharmacologically compatible salts with common acids.

Som vanlige syrer for dannelse av farmakologisk forlike lige salter kan for eksempel anvendes saltsyre, salpetersyre, svovelsyre, fosforsyre, eddiksyre, melkesyre, sitronsyre og salicylsyre. 12 3 Fortrinnsvis er substituentene R , R og R i 3-, 4- og 5-stilling i benzenringen. Blant forbindelsene med formel I foretrekkes de hvor R<4>betyr en lavere alkylrest med 1-4 C-atomer eller en benzylrest, og R 5 og R 6, som kan være like eller forskjellige, betyr hydrogen, lavere alkyl med 1-4 C-atomer, benzyl, fenyl eller, sammen med nitrogenatomet som de er bundet til, en polymetylenkjede med 4 eller 5 metylengrupper, som kan være avbrutt av et oksygenatom eller gruppen ^N-Y hvor Y betyr metyl, benzyl eller fenyl, eller 5 6 7 7 R betyr hydrogen og R gruppen -C^H^-SC^NH-R hvor R er As common acids for the formation of pharmacologically compatible salts, for example, hydrochloric acid, nitric acid, sulfuric acid, phosphoric acid, acetic acid, lactic acid, citric acid and salicylic acid can be used. 12 3 Preferably, the substituents R , R and R are in the 3-, 4- and 5-position in the benzene ring. Among the compounds of formula I, preference is given to those where R<4> means a lower alkyl radical with 1-4 C atoms or a benzyl radical, and R 5 and R 6 , which may be the same or different, mean hydrogen, lower alkyl with 1-4 C atoms, benzyl, phenyl or, together with the nitrogen atom to which they are attached, a polymethylene chain with 4 or 5 methylene groups, which may be interrupted by an oxygen atom or the group ^N-Y where Y means methyl, benzyl or phenyl, or 5 6 7 7 R means hydrogen and R the group -C^H^-SC^NH-R where R is

eller en pyrimidin-2-yl-, 4-metyl-pyrimidin-2-yl-, 5-metyl-pyrimidin-2-yl-, 5-isopropyl-pyrimidin-2-yl-, 5-metoksy-pyrimidin-2-yl, 6-metoksy-pyridazin-3-yl, 3-metoksy-pyrazin-2-yl-, 5-metyl-isoksazol-3-yl- eller 2-pyridinyl-rest, ogR^, or a pyrimidin-2-yl-, 4-methyl-pyrimidin-2-yl-, 5-methyl-pyrimidin-2-yl-, 5-isopropyl-pyrimidin-2-yl-, 5-methoxy-pyrimidin-2- yl, 6-methoxy-pyridazin-3-yl, 3-methoxy-pyrazin-2-yl-, 5-methyl-isoxazol-3-yl- or 2-pyridinyl residue, andR^,

2 3 2 3

R og R har de under formel I angitte betydninger.R and R have the meanings given under formula I.

Blant de nevnte forbindelser med formel I foretrekkes 12 3 Among the aforementioned compounds of formula I, 12 3 is preferred

videre de hvor R , R og R betyr hydrogen, metyl eller metoksy, 12 3 og av disse foretrekkes særlig de forbindelser hvor R , R og R befinner seg i stillingene 3, 4 og 5 i benzylresten og er metoksygrupper. further those where R , R and R mean hydrogen, methyl or methoxy, 12 3 and of these, the compounds where R , R and R are in positions 3, 4 and 5 in the benzyl residue and are methoxy groups are particularly preferred.

Forbindelsene med formel I er antimikrobielt aktive ved sykdommer fremkalt av bakterier og protozoer og forsterker, kombinert med sulfonamider, deres antibakterielle virkning. De kan således for eksempel anvendes ved bakterielle sykdommer i åndedrettsorganene, fordøyelsesorganene og urinveiene så vel som ved hals-, nese-, øreinfeksjoner og generelt ved systemiske infeksjonssykdommer og ved malaria. The compounds of formula I are antimicrobially active in diseases caused by bacteria and protozoa and, combined with sulfonamides, enhance their antibacterial action. They can thus, for example, be used in bacterial diseases of the respiratory organs, digestive organs and urinary tracts as well as in throat, nose and ear infections and in general in systemic infectious diseases and in malaria.

Slike sulfonamider er for eksempel: 2-sulfanilamido-pyridin, 2-sulfanilamido-tiazol, 2-sulfanilamido-pyrimidin, 2-sulfanilamido-4-metyl-pyrimidin, 2-sulfanilamido-4,6-dimetyl-pyrimidin, 4-sulfanilamido-2,6-dimetyl-pyrimidin, 5-sulfanilamido-3,4-dimetyl-isoksazol, 3-sulfanilamido-6-metoksy-pyridazin, 3-sulfanilamido-6-klor-pyridazin, 4-sulfanilamido-2,6-dimetoksy-pyrimidin, 3-sulfanilamido-2-fenyl-pyrazol, 2-sulfanilamido-5-metyl-pyrimidin, 2-sulfanilamido-5-metoksy-pyrimidin, 2-sulfanilamido-5-metyl-isoksazol, 2-sulfanilamido-4,5-dimetyl-oksazol, 2-sulfanilamido-3-metoksy-pyrazin, 4-sulfanilamido-5,6-dimetoksy-pyrimidin, 4-sulfanilamido-3-metoksy-1,2,5-tiadiazol, 4-aminobenzen-sulfonyl-guanidin. Such sulfonamides are, for example: 2-sulfanilamido-pyridine, 2-sulfanilamido-thiazole, 2-sulfanilamido-pyrimidine, 2-sulfanilamido-4-methyl-pyrimidine, 2-sulfanilamido-4,6-dimethyl-pyrimidine, 4-sulfanilamido- 2,6-dimethyl-pyrimidine, 5-sulfanilamido-3,4-dimethyl-isoxazole, 3-sulfanilamido-6-methoxy-pyridazine, 3-sulfanilamido-6-chloro-pyridazine, 4-sulfanilamido-2,6-dimethoxy- pyrimidine, 3-sulfanilamido-2-phenyl-pyrazole, 2-sulfanilamido-5-methyl-pyrimidine, 2-sulfanilamido-5-methoxy-pyrimidine, 2-sulfanilamido-5-methyl-isoxazole, 2-sulfanilamido-4,5- dimethyl-oxazole, 2-sulfanilamido-3-methoxy-pyrazine, 4-sulfanilamido-5,6-dimethoxy-pyrimidine, 4-sulfanilamido-3-methoxy-1,2,5-thiadiazole, 4-aminobenzenesulfonyl-guanidine.

Forbindelsene med formel I og deres salter kan for eksempel blandes med de nevnte sulfonamider i forskjellige mengde-forhold, idet forholdet mellom forbindelse med formel I og sulfonamid kan variere fra 1:10 til 5:1. Foretrukne blandings-forhold er imidlertid 1:1 til 1:5. Vanligvis anvendes en doser-ing på 20 til 550 mg av en aktiv forbindelse med formel I. The compounds of formula I and their salts can, for example, be mixed with the aforementioned sulfonamides in different proportions, the ratio between compound of formula I and sulfonamide can vary from 1:10 to 5:1. However, preferred mixing ratios are 1:1 to 1:5. Usually a dosage of 20 to 550 mg of an active compound of formula I is used.

De nye forbindelser med formel I fremstilles i henhold til oppfinnelsen ved metoder som er vanlige for fremstilling av amidiner, slik som for eksempel beskrevet i Houben-Weyl "Methoden der organischen Chemie", bind 11/2, ved at en imidsyre-ester med den generelle formel II The new compounds of formula I are prepared according to the invention by methods that are common for the preparation of amidines, such as described for example in Houben-Weyl "Methoden der organischen Chemie", volume 11/2, in that an imidic acid ester with the general formula II

1 2 3 4 8 hvor R , R , R og R har de ovenfor angitte betydninger, og R betyr lavere alkyl med 1-4 C-atomer1 eller benzyl, omsettes med et amin med den generelle formel III hvor R og R^ har de ovenfor angitte betydninger, til et amidin med den generelle formel I ■ 1 2 3 4 8 where R , R , R and R have the meanings given above, and R means lower alkyl with 1-4 C atoms1 or benzyl, is reacted with an amine of the general formula III where R and R^ have the meanings given above, to an amidine of the general formula I ■

og derefter overføres eventuelt den erholdte forbindelse til et farmakologisk forlikelig syreaddisjonssalt med en egnet syre.' and then optionally the compound obtained is transferred to a pharmacologically compatible acid addition salt with a suitable acid.'

Imidsyreesteren med den generelle formel II og fremstilling av denne er beskrevet i vår norske patentansøkning 78.2341. The imidic acid ester with the general formula II and its preparation are described in our Norwegian patent application 78.2341.

Aminer med formel III kan for eksempel være: ammoniakk, métylamin, dimetylamin, dietylamin, benzylamin, 3,4,5-trimetoksybenzylamin, N-fenyl-piperazin, furfurylamin, cykloheksylamin, pyrrolidin, piperidin, morfolin, anilin og sulfonamid slik som f.eks. 2-sulfanilamino-pyrimidin, 2-sulfanilamido-4-metyl-pyrimidin, 2-sulfanilamido-5-metyl-pyrimidin, 2-sulfanilamido-5-isopropyl-pyrimidin, 2-sulfanilamido-5-metoksy-pyrimidin, 3-sulfanilamido-6-metoksy-pyridazin, 2-sulfanilamido-3-metoksy-pyrazin, 3-sulfanilamido-5-metyl-isoksazol og 2-sulfanilamido-pyridin. Amines of formula III can be, for example: ammonia, methylamine, dimethylamine, diethylamine, benzylamine, 3,4,5-trimethoxybenzylamine, N-phenyl-piperazine, furfurylamine, cyclohexylamine, pyrrolidine, piperidine, morpholine, aniline and sulfonamide such as e.g. e.g. 2-Sulfanilamino-pyrimidine, 2-Sulfanilamido-4-methyl-pyrimidine, 2-Sulfanilamido-5-methyl-pyrimidine, 2-Sulfanilamido-5-isopropyl-pyrimidine, 2-Sulfanilamido-5-methoxy-pyrimidine, 3-Sulfanilamido- 6-methoxy-pyridazine, 2-sulfanilamido-3-methoxy-pyrazine, 3-sulfanilamido-5-methylisoxazole and 2-sulfanilamido-pyridine.

Fremstilling av disse forbindelser kan skje med eller uten oppløsningsmiddel. Mulige oppløsningsmidler kan f.eks. være pyridin, etanol eller vann eller blandinger av disse opp-løsningsmidler. Reaksjonstemperaturene ligger mellom 0 og 150°C, fortrinnsvis mellom 20 og 120°C resp. ved temperaturer opp til det anvendte oppløsningsmiddels kokepunkt. Preparation of these compounds can take place with or without a solvent. Possible solvents can e.g. be pyridine, ethanol or water or mixtures of these solvents. The reaction temperatures are between 0 and 150°C, preferably between 20 and 120°C or at temperatures up to the boiling point of the solvent used.

Hvis man for eksempel anvender N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetamidsyreetylester og anilin som utgangsstoffer, kan reaksjonsforløpet illustreres ved hjelp av følgende formelskjema: If, for example, N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetamide ethyl ester and aniline are used as starting materials, the course of the reaction can be illustrated using the following formula:

For påvisning av virkningen ble de nye forbindelser undersøkt ved dyreforsøk efter modell av den såkalte Aronson-Sepsis, hvor infisering foretas med Streptococcus agalactiae, og sammenligning ble gjort med. den kjente forbindelse trimetoprim. For dette formål ble grupper på hver 30 hunnmus infisert med en dødelig dose av Streptococcus agalactiae 7941 og behandlet 2 timer efter infeksjonen méd en blanding av 300 mg 2-sulfanilamido-4,5-dimetyl-oksazol + 60 mg'av en av forbindelsene fremstilt ifølge oppfinnelsen. Foruten en ubehandlet kontrollgruppe ble en annen gruppe behandlet med en blanding av 300 mg 2-sulfanilamido-4,5-dimetyl-oksazol + 60 mg trimetoprim som tjente som referansestoff. Efter 44 timer ble antall overlevende dyr bestemt, og dette tall ble dividert med det antall overlevende dyr i den gruppe som var behandlet med referansestoffet. Den således oppnådde tallverdi (trimetoprimfaktor) er et mål for virkningen av de nye forbindelser sammenlignet med trimetoprim. F = 2 betyr således at forbindelsen er dobbelt.så aktiv som trimetoprim. Av den følgende tabell fremgår det at de nye forbindelser er opp til 5,4 ganger så aktive som trimetoprim. To demonstrate the effect, the new compounds were examined in animal experiments based on the model of the so-called Aronson-Sepsis, where infection is carried out with Streptococcus agalactiae, and comparison was made with. the known compound trimethoprim. For this purpose, groups of 30 female mice each were infected with a lethal dose of Streptococcus agalactiae 7941 and treated 2 hours after the infection with a mixture of 300 mg of 2-sulfanilamido-4,5-dimethyl-oxazole + 60 mg of one of the compounds prepared according to the invention. In addition to an untreated control group, another group was treated with a mixture of 300 mg of 2-sulfanilamido-4,5-dimethyl-oxazole + 60 mg of trimethoprim which served as a reference substance. After 44 hours, the number of surviving animals was determined, and this number was divided by the number of surviving animals in the group treated with the reference substance. The thus obtained numerical value (trimethoprim factor) is a measure of the effect of the new compounds compared to trimethoprim. F = 2 thus means that the compound is twice as active as trimethoprim. The following table shows that the new compounds are up to 5.4 times as active as trimethoprim.

Forbindelsene fremstilt ifølge oppfinnelsen kan anvendes i kjemoterapeutiske midler som ved siden av vanlige bære- og fortynningsmidler inneholder en forbindelse med formel I, spesi-elt i kombinasjon med et sulfonamid, som aktive stoffer. The compounds produced according to the invention can be used in chemotherapeutic agents which, in addition to usual carriers and diluents, contain a compound of formula I, especially in combination with a sulfonamide, as active substances.

De kjemoterapeutiske midler resp. preparater fremstilles med de vanlige bærestoffer eller fortynningsmidler og de vanlig anvendte farmasøytisk-tekniske hjelpestoffer i henhold til den ønskede administrerings form. The chemotherapeutic agents or preparations are prepared with the usual carriers or diluents and the commonly used pharmaceutical-technical excipients according to the desired form of administration.

De foretrukne preparater består av en tilberedelsesform som er egnet for oral administrering. Slike tilberedelsesformer er f.eks. tabletter, filmtabletter, dragéer, kapsler, piller, pulvere, oppløsninger eller suspensjoner. The preferred preparations consist of a preparation form suitable for oral administration. Such forms of preparation are e.g. tablets, film-coated tablets, dragées, capsules, pills, powders, solutions or suspensions.

Eksempel 1Example 1

16,2 g N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester oppløses i 120 ml pyridin og tilsettes 14 ml mettet, etanolisk ammoniakkoppløsning og omrøres i 12 timer ved 70°C. Efter inndampning i vakuum omkrystalliseres 16.2 g of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester are dissolved in 120 ml of pyridine and 14 ml of saturated, ethanolic ammonia solution are added and stirred for 12 hours at 70°C. After evaporation in vacuum recrystallize

residuet fra dioksan. Man får 8,6 g (57,7% av det teoretiske) N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetamidin med sm.p. 207°C. the residue from dioxane. 8.6 g (57.7% of the theoretical) of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetamidine with m.p. 207°C.

Eksempel 2Example 2

1,8 g N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester oppvarmes sammen med 0,93 g anilin og 20 ml absolutt etanol under omrøring i 15 timer til kokning under tilbakeløpskjøling, avkjøles og tilsettes 80 ml vann. 1.8 g of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester are heated together with 0.93 g of aniline and 20 ml of absolute ethanol with stirring for 15 hours to boil under reflux, cool and add 80 ml of water.

Man får 1,1 g (53% av det teoretiske) N-[4-amino-5-(3,4,5-trimetoksybenzyl ) -pyrimidin-2-yl]-N'-fenyl-acetamidin med sm.p. 189°C. 1.1 g (53% of the theoretical) of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-phenyl-acetamidine with m.p. 189°C.

Eksempel 3Example 3

1,8 g N-[4-åmino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester omrøres med 20 ml 40%-ig vandig dimetylaminoppløsning i 10 timer ved 50-60°C. Det krystallinske bunnfall frafiltreres, vaskes med vann og omkrystalliseres fra dioksan. Man får 1,24 g (69% av det teoretiske) N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N', N'-dimetyl-acetamidin med sm.p. 220°C. 1.8 g of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester is stirred with 20 ml of 40% aqueous dimethylamine solution for 10 hours at 50-60 °C. The crystalline precipitate is filtered off, washed with water and recrystallized from dioxane. 1.24 g (69% of the theoretical) of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N', N'-dimethylacetamidine with sm .p. 220°C.

Eksempel 4Example 4

Analogt med eksempel 3 ble N-[4-amino-5-(3,4,5-trimetoksybenzyl) -pyrimidin-2-yl]-N',N1-dietyl-acetamidin med sm.p. 154°C fremstilt fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetamidsyre-etylester og dietylamin. Analogously to example 3, N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N',N1-diethylacetamidine with m.p. 154°C prepared from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetamic acid ethyl ester and diethylamine.

Eksempel 5Example 5

1,8 g N-[(4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester suspenderes i 10 ml N-fenylpiperazin og oppvarmes til 65°C inntil alt er oppløst og omrøres dereft.er i 3 timer ved 90-l00°C. Efter avkjøling behandles reaksjonsblandingen med 100 ml dietyleter, det hvite, krystallinske bunnfall frafiltreres og omkrystalliseres fra butylacetat. Man får 1,6 g (67% av det teoretiske) N-t(4-amino-5-(3,4,5-trimetoksybenzyl) -pyrimidin-2-yl]-N1,N'-(3-aza-3-fenyl-pentametylen)-acetamidin med sm.p. 197°c. 1.8 g of N-[(4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester is suspended in 10 ml of N-phenylpiperazine and heated to 65°C until everything is dissolved and then stirred for 3 hours at 90-100° C. After cooling, the reaction mixture is treated with 100 ml of diethyl ether, the white, crystalline precipitate is filtered off and recrystallized from butyl acetate. 1.6 g (67% of the theoretical) N-t is obtained (4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N1,N'-(3-aza-3-phenyl-pentamethylene)-acetamidine with m.p. 197°C .

Eksempel 6Example 6

Analogt med eksempel 5 ble N-[4-amino-5-(3,4,5-trimetoksybenzyl) -pyrimidin-2-yl]-N1,N1-tetrametylen-acetamidin med sm.p. 198°C fremstilt fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og pyrrolidin. Analogous to example 5, N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N1,N1-tetramethylene-acetamidine with m.p. 198°C prepared from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and pyrrolidine.

Eksempel 7Example 7

5,4 g N-[ 4r-amino-5-(3 , 4, 5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 1,6 g benzylamin oppløses i 40 ml pyridin og omrøres, i 2 timer ved 90°C. Efter inndampning i vakuum oppløser man residuet i varme i 200 ml etylacetat, gjør oppløsningen klar med aktivt kull og avkjøler. Fra oppløsningen utkrystalliserer 3,2 g (51% av det teoretiske) N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-benzyl-acetamidin med sm.p. 164°C. 5.4 g of N-[4r-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 1.6 g of benzylamine are dissolved in 40 ml of pyridine and stirred for 2 hours at 90°C. After evaporation in a vacuum, the residue is dissolved in heat in 200 ml of ethyl acetate, the solution is made clear with activated charcoal and cooled. From the solution, 3.2 g (51% of the theoretical) N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-benzyl-acetamidine with m.p. . 164°C.

Analogt med eksempel 7 ble fremstilt:Analogous to example 7, the following was produced:

8. N-[4-amino-5-(3,4Y 5-trimetoksybenzyl)-pyrimidin-2-yl]-N1 -(3,4,5-trimetoksybenzyl)-acetamidin med sm.p. 143°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 3 , 4, 5-trimetoksybenzylam.in. 9. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N<1>,N'-(3-oksa-pentametylen)-acetamidin med sm.p. 205°C fra N-[4-amino-5-(3,4,5-trimetpksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og morfolin. 10. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N<1->furfuryl-acetamidin med sm.p. 184°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og furfurylamin. 11. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N<1->cykloheksyl-acetamidin med sm.p. 183°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og cykloheksylamin. 12. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-adamantyl-acetamidin med sm.p. 248°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 1-adamantylamin. 8. N-[4-amino-5-(3,4Y 5-trimethoxybenzyl)-pyrimidin-2-yl]-N 1 -(3,4,5-trimethoxybenzyl)-acetamidine with m.p. 143°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 3,4,5-trimethoxybenzylamine. 9. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N<1>,N'-(3-oxa-pentamethylene)-acetamidine with m.p. 205°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and morpholine. 10. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N<1->furfuryl-acetamidine with m.p. 184°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and furfurylamine. 11. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N<1->cyclohexyl-acetamidine with m.p. 183°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and cyclohexylamine. 12. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-adamantyl-acetamidine with m.p. 248°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 1-adamantylamine.

Eksempel 13Example 13

10,8 g N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetamidsyre-etylester oppløses sammen med 4,2 g 2-sulfanilamido-5-metoksy-pyrimidin (sulfametoksydiazin) i 80 ml pyridin og omrøres i 12 timer under tilbakeløpskjøling, og reaksjonsblandingen inndampes derefter i vakuum. Efter opp-løsning av residuet i varm aceton og behandling med aktivt kull utkrystalliserer 5,43 g (60,8% av det teoretiske) N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(5-metoksy-pyrimidiri-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 218°C. 10.8 g of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetamidic acid ethyl ester are dissolved together with 4.2 g of 2-sulfanilamido-5-methoxy-pyrimidine ( sulfamethoxydiazine) in 80 ml of pyridine and stirred for 12 hours under reflux, and the reaction mixture is then evaporated in vacuo. After dissolving the residue in hot acetone and treatment with activated charcoal, 5.43 g (60.8% of the theoretical) N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidine-2 crystallizes out -yl]-N'-[4-(5-methoxy-pyrimidiri-2-yl)-sulfonamido]-phenyl-acetamidine with m.p. 218°C.

Analogt med eksempel 13 ble fremstilt:Analogously to example 13, the following was produced:

14. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(5-metyl-pyrimidin-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 192°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 2-sulfanilamido-5-metyl-pyrimidin (sulfaperin). 15. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(pyrimidin-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 178°C (spalt.) fra N-[ 4-amino-5-(3 , 4, 5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 2-sulfanilamido-pyrimidin (sulfadiazin). 16. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(4-metyl-pyrimidin-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 162°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-. pyrimidin-2-yl]-acetimidsyre-etylester og 2-sulfanilamido-4- metyl-pyrimidin (sulfamerazin). 17. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-(4-sulfonylguanidino)-fenyl-acetamidin med sm.p. 246°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 4-aminobenzensulfonylguanidin (sulfaguanidin). 18. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N<1->[4-(5-metyl-isoksazol-3-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 155°C fra N-[ 4-amino-5-(3 , 4, 5-trimetoksybenzyl,) - pyrimidin-2-yl]-acetimidsyre-etylester og 3-sulfanilamido-5- metyl-isoksazol (sulfametoksazol). 19. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(6-metoksy-pyridazin-3-yl)-sulfonamido]-fenyl-acetamidin rried sm.p.l68°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 3-sulfanilamido-6- metoksy-pyridazin (sulfametoksy-pyridazin). 20. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(pyridin-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 237°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 2-sulfanilamido-pyridin (sulfapyridin). 21. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(5-isopropyl-pyrimidin-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 201°C fra N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-acetimidsyre-etylester og 2-sulfanilamido-5-isopropyl-pyrimidin. 22. N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N'-[4-(3-metoksy-pyrazin-2-yl)-sulfonamido]-fenyl-acetamidin med sm.p. 148°C (spalt.) fra N-[ 4-amino-5-(3 , 4, 5-trimetoksybenzyl)-pyrimidiir-2-yl]-acetimidsyre-etylester og 2-sulfanilamido-3-metoksypyrazin (sulfametoksypyrazin, sulfalen). 14. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(5-methyl-pyrimidin-2-yl)-sulfonamido]-phenyl -acetamidine with m.p. 192°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 2-sulfanilamido-5-methyl-pyrimidine (sulfaperine). 15. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(pyrimidin-2-yl)-sulfonamido]-phenyl-acetamidine with sm .p. 178°C (dec.) from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 2-sulfanilamido-pyrimidine (sulfadiazine). 16. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(4-methyl-pyrimidin-2-yl)-sulfonamido]-phenyl -acetamidine with m.p. 162°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-. pyrimidin-2-yl]-acetimidic acid ethyl ester and 2-sulfanilamido-4-methylpyrimidine (sulfamerazine). 17. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-(4-sulfonylguanidino)-phenylacetamidine with m.p. 246°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 4-aminobenzenesulfonylguanidine (sulfaguanidine). 18. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N<1->[4-(5-methyl-isoxazol-3-yl)-sulfonamido] -phenylacetamidine with m.p. 155°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl,)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 3-sulfanilamido-5-methylisoxazole (sulfamethoxazole). 19. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(6-methoxy-pyridazin-3-yl)-sulfonamido]-phenyl -acetamidine rried m.p.168°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 3-sulfanilamido-6-methoxy-pyridazine (sulfamethoxy-pyridazine). 20. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(pyridin-2-yl)-sulfonamido]-phenyl-acetamidine with sm .p. 237°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 2-sulfanilamido-pyridine (sulfapyridine). 21. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(5-isopropyl-pyrimidin-2-yl)-sulfonamido]-phenyl -acetamidine with m.p. 201°C from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-acetimidic acid ethyl ester and 2-sulfanilamido-5-isopropyl-pyrimidine. 22. N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N'-[4-(3-methoxy-pyrazin-2-yl)-sulfonamido]-phenyl -acetamidine with m.p. 148°C (dec.) from N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidinyl-2-yl]-acetimidic acid ethyl ester and 2-sulfanilamido-3-methoxypyrazine (sulfamethoxypyrazine, sulfalene) .

Claims (3)

1. Analogifremgangsmåte for fremstilling av. farmakologisk aktive amidino-benzylpyrimidiner med den generelle formel I 1. Analogy method for the production of. pharmacologically active amidino-benzylpyrimidines of the general formula I 12 3 hvor R , R og R , som kan være like eller forskjellige fra hverandre, betyr hydrogen, metyl, metoksy eller klor, 4 R betyr alkyl med 1-6 C-atomer eller benzyl, ogR^ og R^, som kan være like eller forskjellige fra hverandre, betyr hydrogen, lavere alkyl med 1-4 C-atomer, eventuelt substituert benzyl eller fenyl, cykloheksyl, adamantyl eller furfuryl, 5 6 7 7 eller en av restene R eller R gruppen -C^ H^ -SC^ -NH-R hvor R betyr 12 3 where R , R and R , which may be the same or different from each other, mean hydrogen, methyl, methoxy or chlorine, 4 R means alkyl with 1-6 C atoms or benzyl, and R^ and R^, which may be the same or different from each other, means hydrogen, lower alkyl with 1-4 C atoms, optionally substituted benzyl or phenyl, cyclohexyl, adamantyl or furfuryl, 5 6 7 7 or one of the residues R or R the group -C^ H^ -SC^ -NH-R where R means eller en heterocyklisk ring med 1- til 3 heteroatomer som kan være like eller forskjellige fra hverandre og er nitrogen eller oksygen, og kan være substituert med klor, alkyl med 1 til 4 karbonatomer eller metoksy og består av 5-6 ringledd, eller R 5 og R 6 sammen med nitrogenatomet som de er bundet til, danner en mettet, heterocyklisk ring med 5-7 ledd som eventuelt kan inne-holde et oksygenatom eller-gruppen >N-Y hvor Y betyr metyl, benzyl eller fenyl, og farmakologisk forlikelige salter med vanlige syrer, karakterisert *ved at en forbindelse med den generelle formel II or a heterocyclic ring with 1 to 3 heteroatoms which may be the same or different from each other and is nitrogen or oxygen, and may be substituted by chlorine, alkyl with 1 to 4 carbon atoms or methoxy and consists of 5-6 ring members, or R 5 and R 6 together with the nitrogen atom to which they are bound, form a saturated, heterocyclic ring with 5-7 members which may optionally contain an oxygen atom or the group >N-Y where Y means methyl, benzyl or phenyl, and pharmacologically compatible salts with common acids, characterized *in that a compound of the general formula II 1 2 3 4 8 hvor.R , R , R og R har den ovenfor angitte betydning, og R betyr lavere alkyl med 1-4 C-atomer eller benzyl, omsettes med et amin med formel III ^R 5 H-N (III) 5 6 hvor R og R har den ovenfor angitte betydning, eventuelt i nær-vær av et oppløsningsmiddel, og eventuelt overføres de erholdte forbindelser til et farmakologisk forlikelig salt med en egnet syre. 1 2 3 4 8 where. R , R , R and R have the above meaning, and R means lower alkyl with 1-4 C atoms or benzyl, is reacted with an amine of formula III ^R 5 H-N (III) 5 6 where R and R have the above meaning, possibly in the presence of a solvent, and optionally the compounds obtained are transferred to a pharmacologically compatible salt with a suitable acid. 2. Fremgangsmåte som angitt i krav 1 for fremstilling av N-[4-amino-5-(3,4,5-trimetoksybenzyl)-pyrimidin-2-yl]-N <1-> [4-(5-metyl-pyrimidin-2-yl)-sulfonamido]-fenyl-acetamidin, karakterisert ved at det anvendes utgangs-12 3 materialer hvor R , R og R betyr henholdsvis 3-, 4- og 5-metoksy, R betyr metyl, R5 betyr hydrogen og R betyr [4-(5-metyl-pyrimidin-2-yl)-sulfonamido]-fenyl. • 2. Process as stated in claim 1 for the preparation of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N <1-> [4-(5-methyl- pyrimidin-2-yl)-sulfonamido]-phenyl-acetamidine, characterized in that starting-12 3 is used materials where R, R and R respectively mean 3-, 4- and 5-methoxy, R means methyl, R5 means hydrogen and R means [4-(5-methyl-pyrimidin-2-yl)-sulfonamido]-phenyl. • 3. Fremgangsmåte som angitt i krav 1 for fremstilling av N-[4-amino-5-(3,4,5-trimétoksybenzyl)-pyrimidin-2-yl]-N <1-> [4-(pyrimidin-2-yl)-sulfonamido]-fenyl-acetamidin, karakterisert ved at det anvendes utgangs-materialer hvor R 1, R 2 og R 3betyr henholdsvis 3-, 4- og 5-metoksy, R4 betyr metyl, R5 betyr hydrogen og R <6> betyr [4-(pyrimidin-2-yl)-sulfonamido]-fenyl.3. Process as stated in claim 1 for the preparation of N-[4-amino-5-(3,4,5-trimethoxybenzyl)-pyrimidin-2-yl]-N <1-> [4-(pyrimidin-2- yl)-sulfonamido]-phenyl-acetamidine, characterized in that starting materials are used where R 1, R 2 and R 3 mean respectively 3-, 4- and 5-methoxy, R 4 means methyl, R 5 means hydrogen and R <6> means [4-(pyrimidin-2-yl)-sulfonamido]-phenyl.
NO782455A 1977-07-15 1978-07-14 PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE AMIDINO-BENZYLPYRIMIDINES NO782455L (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19772732029 DE2732029A1 (en) 1977-07-15 1977-07-15 NEW AMIDINO-BENZYLPYRIMIDINE, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THEM

Publications (1)

Publication Number Publication Date
NO782455L true NO782455L (en) 1979-01-16

Family

ID=6014014

Family Applications (1)

Application Number Title Priority Date Filing Date
NO782455A NO782455L (en) 1977-07-15 1978-07-14 PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE AMIDINO-BENZYLPYRIMIDINES

Country Status (15)

Country Link
EP (1) EP0000336B1 (en)
JP (1) JPS5419986A (en)
AR (1) AR227759A1 (en)
AT (1) AT360999B (en)
AU (1) AU520820B2 (en)
CA (1) CA1129410A (en)
DE (2) DE2732029A1 (en)
DK (1) DK143273C (en)
FI (1) FI782221A (en)
HU (1) HU179408B (en)
IE (1) IE47022B1 (en)
IL (1) IL55063A0 (en)
IT (1) IT1096976B (en)
NO (1) NO782455L (en)
ZA (1) ZA784012B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2730468A1 (en) * 1977-07-06 1979-01-18 Basf Ag NEW N-PYRIMIDINYL IMIDIC ACID ESTERS, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THEM
US4333936A (en) * 1978-07-03 1982-06-08 Basf Aktiengesellschaft Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof
DE3045720A1 (en) * 1980-12-04 1982-07-08 Basf Ag, 6700 Ludwigshafen N-PYRIMIDINYL-CARBAMINE ACID ESTER, METHOD FOR THE PRODUCTION THEREOF AND MEDICINAL PRODUCTS CONTAINING THE SAME
JPS5915110U (en) * 1982-07-22 1984-01-30 クラリオン株式会社 constant voltage circuit
JPH0618012B2 (en) * 1983-01-25 1994-03-09 セイコーエプソン株式会社 Constant voltage circuit

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4849791A (en) * 1971-10-26 1973-07-13

Also Published As

Publication number Publication date
EP0000336B1 (en) 1981-04-15
IL55063A0 (en) 1978-09-29
AT360999B (en) 1981-02-10
IE47022B1 (en) 1983-11-30
DE2732029A1 (en) 1979-02-01
AR227759A1 (en) 1982-12-15
DE2860614D1 (en) 1981-05-07
ATA513078A (en) 1980-07-15
DK143273B (en) 1981-08-03
AU520820B2 (en) 1982-03-04
CA1129410A (en) 1982-08-10
DK143273C (en) 1981-11-30
ZA784012B (en) 1979-08-29
IT1096976B (en) 1985-08-26
JPS5419986A (en) 1979-02-15
IE781354L (en) 1979-01-15
AU3790378A (en) 1980-01-17
FI782221A (en) 1979-01-16
DK315878A (en) 1979-01-16
EP0000336A1 (en) 1979-01-24
HU179408B (en) 1982-10-28
IT7825382A0 (en) 1978-07-05

Similar Documents

Publication Publication Date Title
DE60118885T2 (en) NITRATE SALTS OF ANTIMICROBIAL ACTIVE SUBSTANCES
Sirisha et al. Facile Synthesis and Antibacterial, Antitubercular, and Anticancer Activities of Novel 1, 4‐Dihydropyridines
DK172884B1 (en) Analogous Process for Preparing 5-Position Substituted 2,4-Diaminopyrimidines and Intermediates for Use
DK150142B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF 5- (2-IMIDAZOLIN-2-YL) -AMINOPYRIMIDINES OR ACID ADDITION SALTS.
NO146335B (en) STAMP TYPE WELDING GENERATOR
US4659818A (en) Intermediates for benzylpyrimidines
KR20100067046A (en) The novel 2, 6-substituted 3-nitropyridine derivatives, the preparation thereof and pharmaceutical composition comprising the same
DE69626682T2 (en) METHOD FOR THE PRODUCTION OF GUANIDINE DERIVATIVES, INTERMEDIATE PRODUCTS THEREFOR AND THEIR PRODUCTION
CN109053591A (en) Diarylmiazines derivatives of biphenyl contenting structure and its preparation method and application
NO782455L (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE AMIDINO-BENZYLPYRIMIDINES
SU571189A3 (en) Method of preparing benzylpyrimidines or salts thereof
CN110437253A (en) Diaryl pyrimidine and cycle compound of biphenyl contenting structure and its preparation method and application
US4048184A (en) 6-Phenyl-2H-pyrazolo[3,4-b]pyridines
EP2029580B1 (en) Novel indol-pyrrol derivatives for the treatment of proliferative and inflammatory diseases
JPS60502003A (en) Preparations containing [(pyridinyl)-2-pyrimidinyl]urea and the same compound effective as cardiotonic agents
DE2452889C2 (en) New benzylpyrimidines, processes for their preparation and pharmaceuticals containing them
CA1037953A (en) 2,4-diamino-5-benzylpyrimidines
EP2933254A1 (en) Novel compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient
DK142848B (en) ANALOGY PROCEDURE FOR PREPARING 2-ACYLAMIDO-4-AMINO - 5-BENZYLPYRIMIDE COMPOUNDS
NO782340L (en) PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE BENZYLPYRIMIDINES
US4333936A (en) Novel amidino-benzylpyrimidines, processes for their manufacture and antibacterial and antiprotozoal use thereof
CZ12097A3 (en) Trifluoromethylquinolinecarboxylic acid derivatives and pharmaceutical composition containing thereof
JPS584025B2 (en) 4;- Alkyldioxyalkylene -5- benzylpyrimidine
Selvakumar et al. Synthesis, characterization and in vitro antibacterial evaluation of 1-(7, 7-dimethyl-2-morpholino-5, 6, 7, 8-tetrahydroquinazolin-4-yl) piperidine-4-carboxamide derivatives
CS244811B2 (en) Production method of new amides of substituted piperazin-1.yl-acetic acid